Braz J Psychiatry July 7, 2026 Alberto Souza Sá Filho, James Oluwagbamigbe Fajemiroye, Antonio Egidio Nardi et al.
Beyond Enthusiasm: Ayahuasca and the Future of Depression Research.
Mexican Journal of Medical Research ICSA July 5, 2026 Omar Azuara-Antonio, Erika Rubí de la Cruz-Elizaldeb, José Eduardo Carmona-Rodriguez et al.
The Psilocybe cubensis mushroom is recognized as the primary source of psilocybin in the Americas, occurring naturally across various regions. This fungus has a long history of use in Mesoamerican rituals due to its capacity to induce altered states of consciousness. The defining characteristic of Psilocybe mushrooms is their psilocybin content. Following ingestion, psilocybin is metabolized...
Clinical pharmacology and therapeutics July 1, 2026 Tijana Stojanovic, Kent W Nilsson, Robert Fredriksson et al.
Interest in ayahuasca and its main component, N,N-Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited. We therefore systematically examined registered interventional trials of DMT, ayahuasca, and DMT combined with...
Progress in Neuro-psychopharmacology and Biological Psychiatry July 1, 2026 Guilherme Lodetti, Rafael Mariano de Bitencourt, Antonio Inserra et al.
BackgroundAlcohol use disorder (AUD) remains difficult to treat with lasting success, leading to growing interest in alternative therapeutic approaches. Psychedelic compounds such as Ayahuasca, a traditional brew used in Indigenous Amazonian ceremonies containing N,N-dimethyltryptamine (DMT) along with monoamine oxidase-inhibiting β-carbolines, have shown promise in reducing addictive...
Zenodo (CERN European Organization for Nuclear Research) July 1, 2026 Schüller Thomas
DMT und Ayahuasca / DMT and Ayahuasca Eigenständiges bilinguales Vollwerk (DE+EN). Transdisziplinäre wissenschaftliche Übersicht zu DMT und Ayahuasca entlang acht Disziplinen, mit expliziter Geltungsstufen-Kennzeichnung (gesichert / wahrscheinlich / offen). **Schwesterwerke (gleiche Struktur):** FORSCH-0291 (LSD) · FORSCH-0350 (Psilocybin) · FORSCH-0351 (Meskalin) **Theorieanker:** FORSCH-0083...